Novacyt
S.A.
("Novacyt", the "Company" or
the "Group")
Notice of Results and Annual
General Meeting
Paris, France,
and Eastleigh and Manchester, UK - 20 May 2024 -
Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international molecular diagnostics company with a broad portfolio
of integrated technologies and services, announces that it will
report its audited financial results for the year ended 31 December
2023 on Thursday, 30 May 2024.
The Company also announces that its Annual
General Meeting ("AGM") will be held at 2pm CEST/1pm BST on
Wednesday, 26 June 2024 as an open virtual meeting. Further details
of the AGM will be provided to shareholders in due
course.
Investor
webinar
An investor webinar presentation by Lyn Rees,
Chief Executive Officer, and Steve Gibson, Chief Financial Officer,
relating to the FY 2023 results will take place at 11.00am
BST on Thursday, 30 May 2024.
The webinar is open to all existing and
potential investors, and will consist of a presentation followed by
a Q&A session, held on the Investor Meet Company platform.
Questions can be submitted pre-event via your Investor Meet Company
dashboard up until 9.00am the day before the meeting or at any time
during the live presentation. Automated French subtitling will be
available throughout the presentation.
Investors can sign up for the webinar
via:
https://www.investormeetcompany.com/novacyt-sa/register-investor
Investors who already follow NOVACYT S.A. on
the Investor Meet Company platform will automatically be
invited.
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
Lyn Rees, Chief Executive
Officer
|
Via Walbrook
PR
|
|
Steve Gibson, Chief Financial
Officer
|
|
|
SP
Angel Corporate Finance LLP (Nominated Adviser and
Broker)
|
+44 (0)20
3470 0470
|
|
Matthew Johnson / Charlie Bouverat
(Corporate Finance)
Vadim Alexandre / Rob Rees
(Corporate Broking)
|
|
|
|
|
|
Deutsche Numis (Joint
Broker)
|
+44 (0)20
7260 1000
|
|
Freddie Barnfield / Duncan Monteith
/ Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick
Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/
y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR
(Financial PR & IR)
Stephanie Cuthbert / Paul McManus
/
Phillip Marriage / Alice
Woodings
|
+44 (0)20
7933 8780 or novacyt@walbrookpr.com
+44
(0)7796 794 663 / +44 (0)7980 541 893
+44
(0)7867 984 082 / +44 (0)7407 804 654
|
|
|
|
|
| |
About Novacyt Group (www.novacyt.com)
Novacyt is an
international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily
focused on the delivery of genomic medicine. The Company
develops, manufactures, and commercialises
a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions
from sample to result across multiple sectors including human
health, animal health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical in vitro diagnostic products,
workflows and services focused on three therapeutic
areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex
winter respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size selection DNA
sample preparation platforms and rapid PCR
machines, including:
·
Ranger® Technology: automated DNA sample
preparation and target enrichment technology
MyGo: real-time quantitative PCR
(qPCR) instruments
|
|
Research Use Only
|
Range of services for the research industry:
· Design,
manufacture, and supply of high-performance qPCR assays and
workflows for use in human health, agriculture, veterinary and
environmental, to support global health organisations and the
research industry
·
Pharmaceutical research services: whole genome sequencing (WGS) /
whole exome sequencing (WES)
|
Novacyt is headquartered in Vélizy
in France with offices in the UK (in Stokesley, Eastleigh and
Manchester), Taipei, Singapore, the US and Canada and has a
commercial presence in over 65 countries. The Company is listed on
the London Stock Exchange's AIM market ("NCYT") and on the Paris
Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com
